Kenya Psychosis-Risk Outcomes Study (KePROS): Development of an Accelerated Medicine Partnership Schizophrenia-Aligned Project in Africa.

Journal: Schizophrenia bulletin open

Volume: 5

Issue: 1

Year of Publication: 

Affiliated Institutions:  Department of Psychiatry, Washington University Medical School, St. Louis, MO, USA. African Mental Health Research and Training Foundation, Nairobi, Kenya. Department of Psychiatry, Beth Israel Deaconess Medical Center at Harvard Medical School, Boston, MA, USA.

Abstract summary 

The Accelerating Medicines Partnership Schizophrenia (AMP SCZ) funds a longitudinal study of 43 research sites across 5 continents to develop tools to stratify developmental trajectories of youth at clinical high risk for psychosis (CHR) and identify homogenous targets for future clinical trials. However, there are no sites in Africa, leaving a critical gap in our knowledge of clinical and biological outcomes among CHR individuals.We describe the development of the Kenya Psychosis-Risk Outcomes Study (KePROS), a 5-year NIH-funded project in Kenya designed to harmonize with AMP SCZ. The study will recruit over 100 CHR and 50 healthy participants and conduct multiple clinical and biomarker assessments over 2 years. Capacity building is a key component of the study, including the construction of an electroencephalography (EEG) laboratory and the upgrading of a local 3 T magnetic resonance imaging (MRI) machine. We detail community recruitment, study methodologies and protocols, and unique challenges with this pioneering research in Africa.This paper is descriptive only. Planned future analyses will investigate possible predictors of clinical outcomes and will be compared to results from other global populations.KePROS will provide the research community with a rich longitudinal clinical and biomarker dataset from an African country in the developing Global South, which can be used alongside AMP SCZ data to delineate CHR outcome groups for future treatment development. Training in mental health assessment and investment in cutting-edge biomarker assessment and other technologies is needed to facilitate the inclusion of African countries in large-scale research consortia.

Authors & Co-authors:  Mamah Daniel D Mutiso Victoria V Musyimi Christine C Harms Michael P MP Anokhin Andrey P AP Chen ShingShiun S Torous John J Muyela Levi L Nashed Jerome J Al-Hosni Yazen Y Odera Arthur A Yarber Alaina A Golosheykin Semyon S Faghankhani Masoomeh M Sneed Megan M Ndetei David M DM

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Mamah D. Global burden of schizophrenia. In: Sadock BJ, Sadock VS, Ruiz P, eds. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Vol 1–2. 11th ed. Philadelphia, PA: Wolters Kluwer; 2024. In press.
Authors :  16
Identifiers
Doi : sgae009
SSN : 2632-7899
Study Population
Male,Female
Mesh Terms
Other Terms
AMP SCZ;CHR;EEG;KePROS;Kenya;MRI;clinical high risk;psychosis;schizophrenia
Study Design
Descriptive Study,Longitudinal Study
Study Approach
Country of Study
Kenya
Publication Country
United States